The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review

Anxiety and DepressionPsychosis and Schizophrenia

Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist

Clin Schizophr Relat Psychoses.

Citrome L

doi: 10.3371/1935-1232-10.2.109.

Psychosis and Schizophrenia

A comprehensive review of the genetic and biological evidence supports a role for MicroRNA-137 in the etiology of schizophrenia

Am J Med Genet B Neuropsychiatr Genet.

Sakamoto K, Crowley JJ

doi: 10.1002/ajmg.b.32554.

Aging and Cognitive FunctionsPsychosis and Schizophrenia

Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO

Psychopharmacology (Berl).

Girgis RR, Slifstein M, D'Souza D, Lee Y, Periclou A, Ghahramani P, Laszlovszky I, Durgam S, Adham N, Nabulsi N, Huang Y, Carson RE, Kiss B, Kapás M, Abi-Dargham A, Rakhit A

doi: 10.1007/s00213-016-4382-y

Aging and Cognitive FunctionsPsychosis and Schizophrenia

Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries

Expert Opin Pharmacother.

Garay RP, Citrome L, Samalin L, Liu CC, Thomsen MS, Correll CU, Hameg A, Llorca PM

doi: 10.1517/

Psychosis and Schizophrenia

On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D_2/3 receptor agonist radioligand study

Transl Psychiatry.

Weidenauer A, Bauer M, Sauerzopf U, Bartova L, Nics L, Pfaff S, Philippe C, Berroterán-Infante N, Pichler V, Meyer BM, Rabl U, Sezen P, Cumming P, Stimpfl T, Sitte HH, Lanzenberger R, Mossaheb N, Zimprich A, Rusjan P, Dorffner G, Mitterhauser M, Hacker M, Pezawas L, Kasper S, Wadsak W, Praschak-Rieder N, Willeit M

doi: 10.1038/s41398-019-0681-5.

Further Publications NeurologyFurther Publications Psychiatry

Association of dopamine D_2/3 receptor binding potential measured using PET and [¹¹C]-(+)-PHNO with post-mortem DR_2/3 gene expression in the human brain

Neuroimage.

Komorowski A, Weidenauer A, Murgaš M, Sauerzopf U, Wadsak W, Mitterhauser M, Bauer M, Hacker M, Praschak-Rieder N, Kasper S, Lanzenberger R, Willeit M

doi: 10.1016/j.neuroimage.

Psychosis and Schizophrenia

The critical treatment window of clozapine in treatment-resistant schizophrenia: Secondary analysis of an observational study.

Psychiatry Res.

Yoshimura B, Yada Y, So R, Takaki M, Yamada N

doi: 10.1016/

Psychosis and Schizophrenia

Disrupted relationship between blood glucose and brain dopamine D2/3 receptor binding in patients with first-episode schizophrenia

Neuroimage Clin

Sauerzopf U, Weidenauer A, Dajic I, Bauer M, Bartova L, Meyer B, Nics L, Philippe C, Pfaff S, Pichler V, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Lanzenberger R, Pezawas L, Praschak-Rieder N, Willeit M

doi: 10.1016/j.nicl.2021.102813

Psychosis and Schizophrenia

Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study

Lancet Psychiatry

Fleischhacker WW, Podhorna J, Gröschl M, Hake S, Zhao Y, Huang S, Keefe RSE, Desch M, Brenner R, Walling DP, Mantero-Atienza E, Nakagome K, Pollentier S

doi: 10.1016/S2215-0366(20)30513-7

Related content

Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist

A comprehensive review of the genetic and biological evidence supports a role for MicroRNA-137 in the etiology of schizophrenia

Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO

Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries

On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2/3 receptor agonist radioligand study

Association of dopamine D2/3 receptor binding potential measured using PET and [11C]-(+)-PHNO with post-mortem DR2/3 gene expression in the human brain

The critical treatment window of clozapine in treatment-resistant schizophrenia: Secondary analysis of an observational study.

Disrupted relationship between blood glucose and brain dopamine D2/3 receptor binding in patients with first-episode schizophrenia

Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study

On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D_2/3 receptor agonist radioligand study

Association of dopamine D_2/3 receptor binding potential measured using PET and [¹¹C]-(+)-PHNO with post-mortem DR_2/3 gene expression in the human brain